CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenues:
License and milestone fees	$ 76	$ 6,070
Non-cash royalty revenue related to the sale of future royalties	6,184	5,684
Research and development support	1,354	772
Clinical materials revenue	46	2,325
Total revenues	7,660	14,851
Operating Expenses:
Research and development	32,909	35,132
General and administrative	9,459	8,329
Restructuring charges	4,130
Total operating expenses	46,498	43,461
(Loss) income from operations	(38,838)	(28,610)
Investment income, net	146	51
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(5,018)	(5,143)
Interest expense on convertible senior notes	(1,150)
Other income (expense), net	129	(38)
Net (loss) income	$ (44,731)	$ (33,740)
Basic and diluted net (loss) income per common share (in dollars per share)	$ (0.51)	$ (0.39)
Basic and diluted weighted average common shares outstanding (in shares)	87,102	86,838
Total comprehensive (loss) income	$ (44,731)	$ (33,740)